Annexon (ANNX) vs Bicara Therapeutics (BCAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Annexon (ANNX) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 27.4% versus a loss of 53.2%. Annexon is the larger company by market cap ($591.4 million vs $560.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | BCAX |
|---|---|---|
| Share price | $3.10 | $8.44 |
| Market cap | $591.37M | $560.31M |
| 1-day change | -9.09% | -7.46% |
| YTD return | -38.25% | -49.85% |
| 1-year return | -27.40% | -53.22% |
| 5-year return | -77.37% | — |
| EPS (TTM) | $-1.01 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-206.69M | $-137.95M |
| 52-week high | $7.18 | $30.99 |
| 52-week low | $3.07 | $7.87 |
| Distance from 52-week high | -56.82% | -72.77% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.39% | +281.16% |
| Average volume | 3.36M | 1.20M |
| Shares outstanding | 190.76M | 66.39M |
| Employees | 97 | 103 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed BCAX by 25.8 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
ANNX vs BCAX FAQ
Which is bigger, Annexon or Bicara Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $560.31M for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, ANNX or BCAX?
ANNX returned -27.40% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Bicara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.